Diameril

Quick links to important sections

Diameril

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diameril

What is Diameril? (Glimepiride)

Property Description
Active Ingredient Glimepiride
Form Oral Tablet
Pharmacological Class Sulfonylurea; Oral Hypoglycemic Agent
Common Use Management of Type 2 Diabetes Mellitus
Origin Synthetic Compound (Derivative)

What is Diameril and Its Role in Diabetes Care?

Diameril is a prescription-only medication classified as an oral hypoglycemic agent, specifically Glimepiride, used to manage high blood sugar levels associated with Type 2 Diabetes Mellitus. Its therapeutic utility is intended for adults whose elevated glucose, or hyperglycemia, remains inadequately controlled through diet and exercise alone. The medicine's primary role is to serve as a foundational glucose-lowering agent within a comprehensive management strategy for Non-Insulin-Dependent Diabetes Mellitus (NIDDM). Glimepiride has an established role as a sulfonylurea used to improve glycemic control.

Glimepiride: A Potent Synthetic Sulfonylurea Derivative

Glimepiride, the active ingredient in Diameril, is a synthetic compound that is formulated as an oral tablet for administration. Glimepiride is definitively categorized within the sulfonylurea pharmacological class, specifically identified as a second-generation derivative. This classification highlights its potency and profile, distinguishing it from earlier agents. As a single-ingredient product, its composition confirms its action is mediated internally. Its classification as a sulfonylurea derivative distinguishes it from other drug classes used for diabetes management; it works by increasing insulin secretion from the pancreas.

Primary and Systemic Action of Glimepiride

Glimepiride functions primarily as an insulin secretagogue, meaning its principal action is the stimulation of insulin release from the functioning pancreatic beta cells. Beyond stimulating the pancreas, Glimepiride also exerts key extra-pancreatic effects. These systemic effects enhance the ability of peripheral tissues to efficiently take up and utilize glucose from the bloodstream, leading to a more comprehensive glucose-lowering outcome. This dual mechanism is a differentiating factor within the sulfonylurea class, recognized for providing effective systemic control of glucose.

Regulatory References

  1. Glimepiride: MedlinePlus Drug Information
  2. Glimepiride FDA Drug Label

What side effects are possible with Diameril?

Possible Side Effects and Safety Information

Diameril (Glimepiride) has an officially documented safety profile characterized primarily by the risk of hypoglycemia (low blood sugar), which is classified as the most common adverse reaction, stemming from the drug's mechanism as an insulin secretagogue. This forms the central focus of the medicine's safety overview in regulatory documents.


Official Adverse Reaction Categories

Adverse reactions are categorized by frequency and the physiological system affected, as defined by government regulatory standards.

Frequency Classification Examples of Adverse Reactions
Common Hypoglycemia, Headache, Dizziness
Uncommon Transient visual disturbances, Gastrointestinal symptoms (nausea, vomiting)
Rare Changes in blood cell counts (e.g., leukopenia, thrombocytopenia)
Very Rare Agranulocytosis, Hepatitis, Cholestatic Jaundice

Serious Adverse Reactions and Systemic Risks

The label documents risks of serious adverse reactions, although these are typically rare or very rare. These include severe forms of hypoglycemia and rare hematologic risks, such as agranulocytosis and pancytopenia, which affect the blood and lymphatic system. Severe hepatic dysfunction, including hepatitis and jaundice, is also officially listed as a very rare risk.

Safety Constraints and Considerations

The official prescribing information identifies specific patient populations and conditions that require careful consideration. Safety-related constraints indicate that Diameril is contraindicated in cases of Type 1 Diabetes Mellitus, Diabetic Ketoacidosis, and severe renal or hepatic function disorders. The risk of hypoglycemia may be increased in elderly patients and those with impaired renal function. Furthermore, transient visual disturbances are often noted at the start of treatment as blood glucose levels stabilize.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory documentation for Diameril ( Glimepiride) describes specific manifestations and the required emergency actions following an overdose. An overdose primarily results in a severe and prolonged hypoglycemic state (low blood glucose), which is the principal documented finding.

Documented Overdose Manifestations

Symptoms are characteristic of severe hypoglycemia, including central nervous system effects such as headache, lethargy, drowsiness, nausea, and vomiting. Physical signs like tremor, diaphoresis (sweating), and tachycardia (rapid heartbeat) are also officially documented. Severe and prolonged hypoglycemia can escalate to life-threatening outcomes, including coma, convulsions, and loss of consciousness.

Required Emergency Actions

The official guidance mandates that any suspected overdose or manifestation of hypoglycemia requires immediate medical attention. If a conscious person exhibits symptoms, the administration of oral carbohydrates is required. If the person is unconscious, the required action is to seek immediate help for the administration of concentrated glucose intravenously. Management is officially described as symptomatic and supportive treatment. Furthermore, prolonged hospital observation is required, often for 24 to 72 hours, due to the documented risk of relapse into severe hypoglycemia. Procedures such as gastric lavage and activated charcoal are described as potentially necessary. No specific antidote is known for Glimepiride overdose. Infants, children, and adolescents are noted to be particularly susceptible to severe effects and require exceptional monitoring.

Therapeutic Uses of Diameril

What Diameril Treats: Main Uses and Benefits

Diameril (Glimepiride) is commonly used alongside diet and exercise for managing Type 2 Diabetes Mellitus (T2DM) in adults. It is a foundational therapeutic agent applied when elevated blood glucose levels (hyperglycemia) persist despite initial lifestyle measures. The medication addresses symptoms related to systemic imbalance, specifically high glucose readings, which include both fasting and after-meal levels. The use of this agent may be part of symptomatic management to achieve a desired therapeutic range.

In clinical settings, it is often used when additional management of discomfort is required, either as a single agent or added to a combination therapy (such as with metformin or insulin). This therapeutic support contributes to easing the overall symptom load and may assist with maintaining functional stability. This support helps improve day-to-day comfort during symptomatic periods. Diameril contributes to a more stable metabolic state over time, which supports the goal that the patient's long-term glucose average (HbA1c) may be part of symptomatic management to help ease symptoms related to systemic imbalance.

Quick Fact: Relief for Hyperglycemia
Primary Use: Assists with managing elevated blood glucose.
Key Benefit: Assists with maintaining functional stability.
Context: Commonly used when initial lifestyle changes are insufficient.

Regulatory References

  1. DailyMed (NIH) for Glimepiride

Eligibility and Restrictions for Use

Who can and cannot use Diameril?

Diameril (Glimepiride) is officially authorized for use only in Adults diagnosed with Type 2 Diabetes Mellitus (T2DM) as an adjunct to diet and exercise. Official regulatory documents strictly define specific contraindications and limitations for all other populations.


Contraindicated Populations

Use is strictly prohibited for patients with Type 1 Diabetes Mellitus or acute conditions like Diabetic Ketoacidosis. It is also contraindicated for those with a known allergy to Glimepiride or a history of allergy to sulfonamide derivatives. For patients with severe renal or hepatic function disorders, use is prohibited, and a changeover to insulin therapy is officially required.


Age and Physiological Restrictions

Use is not established in children under 8 years of age and is not recommended for children and adolescents aged 8 to 17 years. Due to risk concerns, use during pregnancy is contraindicated, and it is not recommended for breastfeeding mothers. Older adults are particularly susceptible to hypoglycemia, meaning use requires caution and careful monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug, drug-food, and drug-substance interactions for Diameril (Glimepiride). These interactions are classified by their potential to significantly alter the drug's effect on blood glucose or change its concentration in the body.

Pharmacodynamic and Pharmacokinetic Interactions

Interactions often involve pharmacodynamic modification, where co-administered agents either potentiate (increase) or attenuate (decrease) the blood-glucose-lowering effect. Numerous drug classes are documented to potentially cause these changes, including other antidiabetic agents, Coumarin anticoagulants, and diuretics.

Pharmacokinetic interactions primarily involve the CYP2C9 enzyme pathway, where inhibitors (e.g., Fluconazole) can increase Glimepiride's exposure, and inducers (e.g., Rifampicin) can decrease it.

Specific Restrictions and Constraints

  • Contraindicated Combination: Co-administration with oral Miconazole is prohibited due to the risk of severe hypoglycemia.
  • Absorption Interference: To prevent a documented reduction in Glimepiride exposure, it must be administered at least 4 hours prior to taking Colesevelam.
  • Substance Constraints: Alcohol can potentiate the hypoglycemic effect. Administration with food slightly reduces the maximum concentration and total exposure of Glimepiride.

Mechanism of Action

Direct Modulation of Pancreatic K ATP Channels

Diameril (Glimepiride) initiates its primary action by functioning as an inhibitor on the Sulfonylurea Receptor 1 ( SUR1), a specific molecular component of the ATP-sensitive potassium channel ( K ATP channel) located on pancreatic beta cells. This binding rapidly closes the channel, preventing the outward movement of potassium ions ( K^+) and causing membrane depolarization. This cellular event triggers the opening of voltage-gated calcium channels, resulting in a crucial calcium ion ( Ca^2+) influx. The influx acts as the signal that forces the exocytosis of pre-formed insulin vesicles into the circulation. This secretory mechanism is strictly dependent on the presence of viable, functioning beta cells.

Modulation of Peripheral Glucose Utilization

Beyond stimulating insulin secretion, Glimepiride exerts extra-pancreatic effects that increase the utilization of glucose by peripheral tissues, specifically skeletal muscle and fat. This mechanism, which involves modulating responsiveness at the tissue level, facilitates the transfer of glucose from the circulation. The combination of increased endogenous insulin supply and modified peripheral utilization contributes to systemic glucose modulation.

Dosage and Administration Information

Diameril (Glimepiride) is administered as an oral tablet and is intended for once daily administration, which establishes a consistent treatment pattern. The medication must be taken with breakfast or the first main meal of the day to align its activity with the patient's nutritional intake. The standard starting dose for adults is generally 1 mg or 2 mg taken once per day. The maintenance amount is subsequently determined by the individual's measured glycemic response.

The dose should be increased only in 1 mg or 2 mg increments, with uptitration occurring no more frequently than every one to two weeks. This measured schedule guides the dosage adjustment process. The maximum recommended daily dose for the oral tablet is 8 mg. Specific administration rules exist for certain patient groups: for older adults or those with renal impairment, the starting dose is restricted to 1 mg once daily, requiring cautious, conservative titration.

In cases of a forgotten dose, established usage guidance stipulates that this should not be corrected by increasing the next dose. Finally, a specific procedural condition mandates that Diameril must be administered at least four hours prior to coadministration of the compound Colesevelam. This structured approach defines the long-term, chronic use protocol.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Diameril (Glimepiride)

Findings described here reflect group patterns, not personal outcomes or clinical predictions.

Evidence for Use in Type 2 Diabetes Mellitus (T2DM)

The use of Glimepiride was studied in research exploring high blood sugar levels in adults with Type 2 Diabetes (T2DM). The initial evidence supporting its use was evaluated in randomized controlled trials (RCTs). These studies monitored the measurement of surrogate glycemic biomarkers, and research examined its use both as a single treatment (monotherapy) and as an addition to other foundational treatments like metformin (combination studies).

The studies monitored the measurement of surrogate glycemic biomarkers. This includes following the patterns in Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG), which are measurements used to track long-term and short-term glucose patterns, respectively. Furthermore, studies also monitored outcomes related to the body's internal response to glucose, such as changes in C-peptide levels, which contribute to the broader evidence landscape.

Long-Term Research and Durability of Follow-up

To understand the effects of Diameril over many years, research examined large-scale, multi-year comparative effectiveness trials and observational cohort studies. These studies typically follow patients for several years, sometimes up to four to seven years. These investigations were applied in research contexts involving fluctuating or unstable symptoms, with researchers monitoring outcomes such as the incidence rates of major adverse cardiovascular events (MACE).

Studies monitored whether the initial changes measured in the lab tests evolved in the observed populations over extended periods. While these large studies provide context, the follow-up durations were limited compared to the lifetime management of a chronic condition.

Research in Special Patient Populations

Specific research and subgroup analyses were evaluated in certain patient groups. For instance, studies explored the use of Glimepiride in older adults (typically those over 65 years) to understand potential differences in how the medicine was observed in these groups. In addition, Glimepiride was studied for individuals with Type 2 Diabetes and a high risk of cardiovascular disease. Data for certain groups remain insufficient, particularly for children or adolescents, as most established research has focused on adults.

Gaps and Uncertainties in Existing Research

The existing evidence highlights what is known — and what is still uncertain. Evidence is limited regarding the direct, long-term comparative effects of Glimepiride on the progression of microvascular complications. While large trials data show patterns related to cardiovascular outcomes, the research does not determine whether an individual will respond similarly, and findings reflect the specific conditions under which they were conducted. Furthermore, studies often report changes in body weight measured during the study period, which was an outcome observed in some studies.

Frequently Asked Questions (FAQ)

Common questions about Diameril (FAQ)


Q: How long does it typically take for Diameril to start working?

A: Official product information indicates that a mild blood glucose-lowering effect is generally noted following a single dose. The time required to reach the maximum blood glucose-lowering effect has been noted as approximately two to three hours after administration.


Q: Is Diameril intended to be taken for a long time or just short-term?

A: Diameril is indicated as a treatment for Type 2 Diabetes Mellitus, which is a chronic condition. For this reason, regulatory documents suggest that the medication is intended for use in a chronic condition and is often managed over the long term.


Q: Are there any common over-the-counter pain relievers that should be avoided with Diameril?

A: Regulatory documents list certain drug classes that can potentiate (increase) the blood glucose-lowering effect, which increases the risk of hypoglycemia (low blood sugar). Common pain relievers such as salicylates and certain non-steroidal anti-inflammatory agents (NSAIDs) are in this category, and it is noted that caution may be necessary when they are co-administered.


Q: What are the most commonly reported side effects of Diameril?

A: Based on information from clinical trials, the most commonly reported adverse reactions include hypoglycemia (low blood sugar), headache, and dizziness. Hypoglycemia is described as the most significant adverse reaction stemming from the drug's mechanism.


Q: Are the side effects of Diameril generally mild or more serious?

A: The most common side effects, like headache and dizziness, are typically considered mild. However, official information highlights that the most significant risk is hypoglycemia, and the label documents rare but serious side effects, such as severe allergic reactions or blood disorders.


Q: Can I take Diameril with common vitamins or supplements?

A: Official information advises patients to inform their healthcare provider about all medications, including vitamins and herbal products. This is because certain substances may affect blood glucose levels or alter how Glimepiride works in the body. Therefore, it is noted that a healthcare provider should be informed before use.


Q: Are there specific foods or drinks that interact with Diameril?

A: Official documents state that alcohol can potentiate the drug's glucose-lowering effect. While the medication is required to be taken with the first main meal of the day, food itself may slightly reduce the maximum concentration of the drug in the body.


Q: What kind of studies support the use of Diameril?

A: The drug’s effectiveness is supported by randomized controlled trials (RCTs) and other clinical studies. These investigations primarily monitored blood glucose biomarkers like HbA1c to evaluate its use as a single treatment (monotherapy) and in combination with other diabetes medications.


Q: Has Diameril been reviewed by regulatory bodies like the FDA or EMA?

A: Yes. The active ingredient in Diameril, Glimepiride, has been reviewed and approved for use in Type 2 Diabetes Mellitus by major regulatory bodies globally, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Q: What is the typical timeframe before the full benefit of Diameril is noticed?

A: The dosage of Diameril is usually adjusted gradually over a period of weeks, depending on the individual’s glycemic response. Clinical studies examined significant reductions in long-term glucose control (measured by HbA1c) after approximately 14 weeks of dosing.


Q: Is it possible to develop a tolerance to Diameril over time?

A: The official label notes that 'secondary failure'—a loss of adequate glucose control after the medicine initially worked well—can occur during chronic treatment. This may indicate a change in the body's response, and it is noted that changes in the body's response may occur.


Q: How do I know if the side effect I am having is serious and listed for Diameril?

A: Serious adverse reactions, though rare, include signs like a severe allergic reaction (such as difficulty breathing or swelling of the face) or severe changes in blood cell counts (such as unexplained bruising or unusual weakness). If these types of serious symptoms are observed, official guidance notes the need for urgent medical evaluation.


Q: What is the difference in how Diameril works compared to [mention another drug]?

A: Diameril is known to have a dual mechanism of action. It primarily stimulates the release of insulin from the pancreas, but it also has extra-pancreatic effects that enhance the ability of muscle and fat tissues to take up and utilize glucose from the bloodstream.


Q: Can I use herbal tea while taking Diameril?

A: Regulatory documents list herbal products as substances that can potentially interact with the drug. Because some herbs may alter blood glucose levels or change the drug’s concentration, it is noted that a healthcare provider should be consulted prior to using any herbal tea or supplement.


Q: How does Diameril fit into the treatment of Type 2 Diabetes compared to other options?

A: Diameril is an established glucose-lowering agent for Type 2 Diabetes, intended to improve glycemic control alongside diet and exercise. Regulatory documents state it can be used as the single primary treatment (monotherapy) or in combination with other foundational treatments, such as metformin or insulin.


Q: Is it common to feel tired when starting Diameril?

A: General fatigue is not listed as a common side effect of the drug itself. However, tiredness and lethargy are documented symptoms of hypoglycemia (low blood sugar), which is the most common adverse reaction. If tiredness is experienced, it is noted to be important to evaluate for other signs of low blood sugar.


Q: Does Diameril affect blood test results?

A: Yes. Regular monitoring of blood glucose and HbA1c levels is required to track the drug's effect. The official label also documents the risk of rare, severe changes in blood cell counts, which necessitates regular monitoring of the blood and lymphatic system.


Q: Is Diameril known to cause weight changes?

A: The official label has noted that weight gain has been observed in some clinical trials and postmarketing reports of Glimepiride, particularly when used in combination with other diabetes medications.


Q: What are the signs that Diameril is not working as expected?

A: Signs that the drug is not providing adequate glucose control (hyperglycemia) may include symptoms such as increased thirst, increased urination, headache, and lethargy or tiredness. These symptoms are associated with inadequate glucose control (hyperglycemia).


Q: Is it normal to have [minor, non-serious symptom] when first taking Diameril?

A: Yes. Transient (temporary) visual disturbances, such as blurred vision, are often noted at the start of treatment. This is generally due to blood glucose levels beginning to stabilize.


Q: Can children or adolescents use Diameril?

A: The official product information states that use is generally not recommended in children and adolescents under 18 years of age. This is due to insufficient safety and effectiveness data in these specific patient populations.


Q: Is there a maximum length of time Diameril is studied for use?

A: While the drug is intended for chronic management of Type 2 Diabetes, the official clinical trials supporting its use often have a follow-up duration limited to a few years. Studies on the active ingredient have followed patient populations for up to four to seven years.


Q: Is Diameril likely to cause sleepiness or drowsiness?

A: The official label lists drowsiness and sleepiness as symptoms that can occur during an episode of hypoglycemia (low blood sugar). Since hypoglycemia is the most common adverse reaction, this potential side effect is tied directly to managing blood sugar levels.


Q: Are there any specific organs that Diameril is known to affect?

A: The drug's primary action targets the pancreas (beta cells) to stimulate insulin. However, the label also documents rare risks of dysfunction related to the liver (hepatitis, jaundice) and the blood/lymphatic system (changes in blood cell counts).


Q: Can Diameril be crushed or chewed?

A: Diameril is formulated as an oral tablet intended to be taken once daily with a meal. Official directions for administration do not mention crushing or chewing the tablet.


Q: Is the long-term safety profile of Diameril well-documented?

A: Yes. The regulatory documents confirm that adverse reactions serious enough to compel discontinuation of therapy are considered uncommon, even during long-term treatment. The drug has been studied over several years in clinical research.


Q: What are the rare but serious side effects of Diameril?

A: Rare but serious risks documented in the official label include severe hypoglycemia (very low blood sugar), severe allergic reactions, severe hepatic dysfunction (liver issues like hepatitis or jaundice), and severe blood disorders like agranulocytosis (a lack of certain white blood cells).

How should Diameril be stored and disposed of?

How to Store and Dispose of Diameril (Glimepiride)

Diameril (Glimepiride) must be stored and handled according to official regulatory specifications to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container, tightly closed, and protected from moisture.
Safety The tablets must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Diameril should be disposed of through a drug take-back program. If a program is unavailable, the tablets must be mixed with an undesirable substance and placed in a sealed bag before discarding in the household trash. Do not flush this medicine down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diameril found in:

A-Z Index: